<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01408576</url>
  </required_header>
  <id_info>
    <org_study_id>SL0012</org_study_id>
    <secondary_id>2010-020859-30</secondary_id>
    <nct_id>NCT01408576</nct_id>
  </id_info>
  <brief_title>Open Label Extension Study of Epratuzumab in Subjects With Systemic Lupus Erythematosus</brief_title>
  <acronym>EMBODY4</acronym>
  <official_title>A Phase 3, Multicenter, Open-label, Extension Study to Assess the Safety and Tolerability of Epratuzumab Treatment in Systemic Lupus Erythematosus Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UCB Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>UCB Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the study is assess the safety and tolerability of long-term
      epratuzumab treatment in subjects with Systemic Lupus Erythematosus (SLE)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Treatment period was extended by 2 years to a total of 4 years and an amendment was prepared
      accordingly.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2011</start_date>
  <completion_date type="Actual">February 2016</completion_date>
  <primary_completion_date type="Actual">February 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Subjects Prematurely Discontinuing Due to a Treatment-emergent Adverse Event (TEAE) During the Treatment Period (Maximum 96 Weeks)</measure>
    <time_frame>During the treatment period (through Week 96)</time_frame>
    <description>A TEAE is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Subjects Prematurely Discontinuing Due to a Treatment-emergent Adverse Event (TEAE) During the Treatment Period (Maximum 96 Weeks)</measure>
    <time_frame>During the treatment period (through Week 96)</time_frame>
    <description>A TEAE is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects Reporting at Least 1 Serious Adverse Event (SAE) During the Treatment Period (Maximum 96 Weeks)</measure>
    <time_frame>During the treatment period (through Week 96)</time_frame>
    <description>A SAE is a treatment-emergent adverse event (TEAE) that the investigator classifies as serious. This includes:
Death
Life-threatening
Significant or persistent disability/incapacity
Congenital anomaly/birth defect (including that occurring in a fetus)
Important medical event that, based upon appropriate medical judgment, may jeopardize the patient or subject and may require medical or surgical intervention to prevent 1 of the other outcomes listed in the definition of serious
Initial inpatient hospitalization or prolongation of hospitalization</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Subjects Reporting at Least 1 Serious Adverse Event (SAE) During the Treatment Period (Maximum 96 Weeks)</measure>
    <time_frame>During the treatment period (through Week 96)</time_frame>
    <description>A SAE is a treatment-emergent adverse event (TEAE) that the investigator classifies as serious. This includes:
Death
Life-threatening
Significant or persistent disability/incapacity
Congenital anomaly/birth defect (including that occurring in a fetus)
Important medical event that, based upon appropriate medical judgment, may jeopardize the patient or subject and may require medical or surgical intervention to prevent 1 of the other outcomes listed in the definition of serious
Initial inpatient hospitalization or prolongation of hospitalization</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Meeting Treatment Response Criteria According to a Combined Response Index</measure>
    <time_frame>At Week 48</time_frame>
    <description>Combined response index is a response variable (yes/no) incorporating the following criteria for achievement of responder status (ie, all criteria must be met to achieve responder status): (1) British Isles Lupus Activity Group (BILAG) improvement, (2) No worsening in Systemic Lupus Erythematosus Activity Index (SLEDAI), (3) No worsening in Physician's Global Assessment of Disease, and (4) No disallowed changes in concomitant medications, with disallowed changes including mainly increases in corticosteroids, immunosuppressants, and antimalarials.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects Meeting Treatment Response Criteria According to a Combined Response Index</measure>
    <time_frame>Week 48</time_frame>
    <description>Combined response index is a response variable (yes/no) incorporating the following criteria for achievement of responder status (ie, all criteria must be met to achieve responder status): (1) British Isles Lupus Activity Group (BILAG) improvement, (2) No worsening in Systemic Lupus Erythematosus Activity Index (SLEDAI), (3) No worsening in Physician's Global Assessment of Disease, and (4) No disallowed changes in concomitant medications, with disallowed changes including mainly increases in corticosteroids, immunosuppressants, and antimalarials.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Meeting Treatment Response Criteria According to a Combined Response Index</measure>
    <time_frame>Week 96</time_frame>
    <description>Combined response index is a response variable (yes/no) incorporating the following criteria for achievement of responder status (ie, all criteria must be met to achieve responder status): (1) British Isles Lupus Activity Group (BILAG) improvement, (2) No worsening in Systemic Lupus Erythematosus Activity Index (SLEDAI), (3) No worsening in Physician's Global Assessment of Disease, and (4) No disallowed changes in concomitant medications, with disallowed changes including mainly increases in corticosteroids, immunosuppressants, and antimalarials.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Percent of Subjects Meeting Treatment Response Criteria According to a Combined Response Index</measure>
    <time_frame>Week 96</time_frame>
    <description>Combined response index is a response variable (yes/no) incorporating the following criteria for achievement of responder status (ie, all criteria must be met to achieve responder status): (1) British Isles Lupus Activity Group (BILAG) improvement, (2) No worsening in Systemic Lupus Erythematosus Activity Index (SLEDAI), (3) No worsening in Physician's Global Assessment of Disease, and (4) No disallowed changes in concomitant medications, with disallowed changes including mainly increases in corticosteroids, immunosuppressants, and antimalarials.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1250</enrollment>
  <condition>Systemic Lupus Erythematosus</condition>
  <arm_group>
    <arm_group_label>Epratuzumab 600 mg per week</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>600 mg infusions delivered weekly for a total of 4 consecutive weeks (cumulative dose 2400 mg) over sixteen 12-week treatment cycles</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Epratuzumab 1200 mg every other week</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1200 mg infusions delivered every other week for a total of 4 weeks (cumulative dose 2400 mg) over sixteen 12 week treatment cycles</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Epratuzumab</intervention_name>
    <description>600 mg infusions delivered weekly for a total of 4 consecutive weeks (cumulative dose 2400 mg) over eight 12-week treatment cycles</description>
    <arm_group_label>Epratuzumab 600 mg per week</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Epratuzumab</intervention_name>
    <description>1200 mg infusions delivered every other week for a total of 4 weeks (cumulative dose 2400 mg) over eight 12 week treatment cycles</description>
    <arm_group_label>Epratuzumab 1200 mg every other week</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject has completed the double-blind study SL0009 (NCT01262365) or SL0010
             (NCT01261793) or terminated prematurely at Week 16 or later in SL0009 or SL0010 due to
             lack of efficacy and would, in the opinion of the investigator, continue to benefit
             from continued epratuzumab treatment

          -  Subject has completed open-label study SL0006 (NCT00383513) or SL0008 (NCT00660881),
             and would, in the opinion of the investigator, continue to benefit from continued
             epratuzumab treatment

          -  Women of childbearing potential must agree to use an acceptable method of birth
             control

        Exclusion Criteria:

          -  Subjects with active, severe, neuropsychiatric SLE, defined as any neuropsychiatric
             element scoring British Isles Lupus Assessment Group Index (BILAG) level A disease

          -  Subjects with active, severe SLE disease activity which involves the renal system

          -  Subjects with concurrent relevant medical conditions like defined chronic infections
             or high risk of new significant infections

          -  Substance abuse or dependence

          -  History of malignant cancer

          -  Subjects with any other condition which, in the investigator's judgment, would make
             the subject unsuitable for inclusion
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>UCB Clinical Trial Call Center</last_name>
    <role>Study Director</role>
    <affiliation>UCB Pharma</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>539</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>557</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>515</name>
      <address>
        <city>Hemet</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>544</name>
      <address>
        <city>Huntington Beach</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>550</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>031</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>051</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>089</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>531</name>
      <address>
        <city>San Leandro</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>594</name>
      <address>
        <city>Thousand Oaks</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>558</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>048</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>037</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>532</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>511</name>
      <address>
        <city>Bridgeport</city>
        <state>Connecticut</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>039</name>
      <address>
        <city>Farmington</city>
        <state>Connecticut</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>042</name>
      <address>
        <city>Aventura</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>514</name>
      <address>
        <city>Brandon</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>090</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>092</name>
      <address>
        <city>DeBary</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>533</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>064</name>
      <address>
        <city>Jupiter</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>070</name>
      <address>
        <city>Ormond Beach</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>084</name>
      <address>
        <city>Palm Harbor</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>518</name>
      <address>
        <city>Plantation</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>585</name>
      <address>
        <city>Port Orange</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>050</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>538</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>087</name>
      <address>
        <city>Vero Beach</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>537</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>044</name>
      <address>
        <city>Duluth</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>590</name>
      <address>
        <city>Idaho Falls</city>
        <state>Idaho</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>052</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>096</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>060</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>513</name>
      <address>
        <city>Lansing</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>599</name>
      <address>
        <city>Lansing</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>047</name>
      <address>
        <city>Saint Clair Shores</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>575</name>
      <address>
        <city>Florissant</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>549</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>596</name>
      <address>
        <city>Nashua</city>
        <state>New Hampshire</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>568</name>
      <address>
        <city>Freehold</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>593</name>
      <address>
        <city>Trenton</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>067</name>
      <address>
        <city>Las Cruces</city>
        <state>New Mexico</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>551</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>553</name>
      <address>
        <city>Great Neck</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>545</name>
      <address>
        <city>Manhasset</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>053</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>577</name>
      <address>
        <city>Roslyn</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>077</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>559</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>058</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>075</name>
      <address>
        <city>Wilmington</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>061</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>071</name>
      <address>
        <city>Middleburg Heights</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>041</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>076</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>097</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>547</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>032</name>
      <address>
        <city>Duncansville</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>093</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>073</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>094</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>535</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>598</name>
      <address>
        <city>Myrtle Beach</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>571</name>
      <address>
        <city>Jackson</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>057</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>574</name>
      <address>
        <city>Amarillo</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>078</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>098</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>570</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>079</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>541</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>563</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>036</name>
      <address>
        <city>Mesquite</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>066</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>562</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>534</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>429</name>
      <address>
        <city>Camperdown</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>427</name>
      <address>
        <city>Clayton</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>430</name>
      <address>
        <city>Liverpool</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>425</name>
      <address>
        <city>Malvern</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>426</name>
      <address>
        <city>Maroochydore</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>106</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>107</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>105</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>104</name>
      <address>
        <city>Liege</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>954</name>
      <address>
        <city>Belo Horizonte</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>956</name>
      <address>
        <city>Campinas</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>955</name>
      <address>
        <city>Goiânia</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>950</name>
      <address>
        <city>Juiz de Fora</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>453</name>
      <address>
        <city>Porto Alegre</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>451</name>
      <address>
        <city>Recife</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>450</name>
      <address>
        <city>Rio de Janeiro</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>952</name>
      <address>
        <city>Rio de Janeiro</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>452</name>
      <address>
        <city>Salvador</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>454</name>
      <address>
        <city>Sao Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>200</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>202</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>203</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>204</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>500</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>502</name>
      <address>
        <city>Hamilton</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>507</name>
      <address>
        <city>Mississauga</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>508</name>
      <address>
        <city>Rimouski</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>506</name>
      <address>
        <city>St. John's</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>504</name>
      <address>
        <city>Toronto</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>218</name>
      <address>
        <city>Olomouc</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>216</name>
      <address>
        <city>Praha 2</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>215</name>
      <address>
        <city>Zlin</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>226</name>
      <address>
        <city>Tallinn</city>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>113</name>
      <address>
        <city>Lille Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>618</name>
      <address>
        <city>Limoges Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>617</name>
      <address>
        <city>Montpellier Cedex 5</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>614</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>116</name>
      <address>
        <city>Pessac</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>616</name>
      <address>
        <city>Toulouse Cedex 9</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>127</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>628</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>633</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>128</name>
      <address>
        <city>Frankfurt</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>126</name>
      <address>
        <city>Freiburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>637</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>632</name>
      <address>
        <city>Herne</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>625</name>
      <address>
        <city>Koln</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>626</name>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>634</name>
      <address>
        <city>Mainz</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>627</name>
      <address>
        <city>Munster</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>129</name>
      <address>
        <city>Plochingen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>636</name>
      <address>
        <city>Roßlau</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>631</name>
      <address>
        <city>Zerbst</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>349</name>
      <address>
        <city>Shatin</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>712</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>716</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>718</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>717</name>
      <address>
        <city>Debrecen</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>711</name>
      <address>
        <city>Szeged</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>715</name>
      <address>
        <city>Szeged</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>713</name>
      <address>
        <city>Zalaegerszeg</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>378</name>
      <address>
        <city>Ashkelon</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>376</name>
      <address>
        <city>Beer Sheva</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>375</name>
      <address>
        <city>Haifa</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>377</name>
      <address>
        <city>Haifa</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>381</name>
      <address>
        <city>Jerusalem</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>382</name>
      <address>
        <city>Kfar Saba</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>380</name>
      <address>
        <city>Rehovot</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>379</name>
      <address>
        <city>Tel Aviv</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>383</name>
      <address>
        <city>Tel-Hashomer</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>149</name>
      <address>
        <city>Ferrara</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>648</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>148</name>
      <address>
        <city>Padova</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>647</name>
      <address>
        <city>Pisa</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>646</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>147</name>
      <address>
        <city>Torino</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>306</name>
      <address>
        <city>Busan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>303</name>
      <address>
        <city>Daegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>308</name>
      <address>
        <city>Daejeon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>301</name>
      <address>
        <city>Incheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>307</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>302</name>
      <address>
        <city>Suwon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>242</name>
      <address>
        <city>Kaunas</city>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>244</name>
      <address>
        <city>Klaipeda</city>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>243</name>
      <address>
        <city>Vilnius</city>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>478</name>
      <address>
        <city>Guadalajara</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>480</name>
      <address>
        <city>Merida</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>976</name>
      <address>
        <city>Mexico City</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>982</name>
      <address>
        <city>Mexico City</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>981</name>
      <address>
        <city>Torreon</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>743</name>
      <address>
        <city>Bydgoszcz</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>744</name>
      <address>
        <city>Czestochowa</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>752</name>
      <address>
        <city>Elblag</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>754</name>
      <address>
        <city>Elbląg</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>746</name>
      <address>
        <city>Katowice</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>748</name>
      <address>
        <city>Lublin</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>750</name>
      <address>
        <city>Lublin</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>742</name>
      <address>
        <city>Poznan</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>747</name>
      <address>
        <city>Szczecin</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>751</name>
      <address>
        <city>Ustron</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>749</name>
      <address>
        <city>Warsaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>263</name>
      <address>
        <city>Brasov</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>260</name>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>262</name>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>264</name>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>757</name>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>758</name>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>261</name>
      <address>
        <city>Cluj-Napoca</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>759</name>
      <address>
        <city>Constanta</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>756</name>
      <address>
        <city>Galati</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>761</name>
      <address>
        <city>Iasi</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>281</name>
      <address>
        <city>Ekaterinburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>779</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>285</name>
      <address>
        <city>Petrozavodsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>284</name>
      <address>
        <city>Saint Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>901</name>
      <address>
        <city>Cape Town</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>902</name>
      <address>
        <city>Durban</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>903</name>
      <address>
        <city>Stellenbosch</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>161</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>661</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>164</name>
      <address>
        <city>Bilbao</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>660</name>
      <address>
        <city>Getafe</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>165</name>
      <address>
        <city>La Laguna</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>662</name>
      <address>
        <city>Las Palmas de Gran Canaria</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>162</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>163</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>664</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>166</name>
      <address>
        <city>Malaga</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>177</name>
      <address>
        <city>Santander</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>663</name>
      <address>
        <city>Santiago de Compostela</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>160</name>
      <address>
        <city>Sevilla</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>659</name>
      <address>
        <city>Vigo</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>325</name>
      <address>
        <city>Changhua</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>326</name>
      <address>
        <city>Chiayi City</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>328</name>
      <address>
        <city>Kaohsiung City</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>330</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>791</name>
      <address>
        <city>Donetsk</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>799</name>
      <address>
        <city>Ivano-Frankivsk</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>790</name>
      <address>
        <city>Kiev</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>794</name>
      <address>
        <city>Kiev</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>797</name>
      <address>
        <city>Kiev</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>792</name>
      <address>
        <city>Lugansk</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>793</name>
      <address>
        <city>Odessa</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>796</name>
      <address>
        <city>Vinnytsya</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>677</name>
      <address>
        <city>Birmingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>178</name>
      <address>
        <city>Brighton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>182</name>
      <address>
        <city>Doncaster</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>179</name>
      <address>
        <city>Leeds</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>181</name>
      <address>
        <city>Romford</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Bulgaria</country>
    <country>Canada</country>
    <country>Czechia</country>
    <country>Estonia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hong Kong</country>
    <country>Hungary</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Lithuania</country>
    <country>Mexico</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Taiwan</country>
    <country>Ukraine</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
  </removed_countries>
  <verification_date>March 2016</verification_date>
  <study_first_submitted>August 1, 2011</study_first_submitted>
  <study_first_submitted_qc>August 1, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 3, 2011</study_first_posted>
  <results_first_submitted>July 20, 2018</results_first_submitted>
  <results_first_submitted_qc>September 3, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">October 3, 2018</results_first_posted>
  <last_update_submitted>September 3, 2018</last_update_submitted>
  <last_update_submitted_qc>September 3, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 3, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Lupus</keyword>
  <keyword>Monoclonal antibody</keyword>
  <keyword>B-Cell immunotherapy</keyword>
  <keyword>Epratuzumab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lupus Erythematosus, Systemic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epratuzumab</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study started to enroll patients in July 2011 and concluded in February 2016.</recruitment_details>
      <pre_assignment_details>Participant Flow refers to the Enrolled Set, that consisted of all subjects who gave informed consent.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Enrollment Cohort 1 Epratuzumab 600 mg Per Week (ES)</title>
          <description>Enrolled Set (ES) of subjects enrolled prior to the approval of Protocol Amendment 2. 600 mg infusions delivered weekly for a total of 4 consecutive weeks (cumulative dose 2400 mg) over sixteen 12-week treatment cycles</description>
        </group>
        <group group_id="P2">
          <title>Enrollment Cohort 2 Epratuzumab 1200 mg Q2W (ES)</title>
          <description>Enrolled Set (ES) of subjects enrolled prior to the approval of Protocol Amendment 2
1200 mg infusions delivered every other week (Q2W) for a total of 4 weeks (cumulative dose 2400 mg) over sixteen 12 week treatment cycles</description>
        </group>
        <group group_id="P3">
          <title>Enrollment Cohort 2 Epratuzumab 600 mg Per Week (ES)</title>
          <description>Enrolled Set (ES) of subjects enrolled prior to the approval of Protocol Amendment 2
600 mg infusions delivered weekly for a total of 4 consecutive weeks (cumulative dose 2400 mg) over sixteen 12-week treatment cycles</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="244"/>
                <participants group_id="P2" count="498"/>
                <participants group_id="P3" count="508"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="56"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="188"/>
                <participants group_id="P2" count="498"/>
                <participants group_id="P3" count="508"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="30"/>
                <participants group_id="P3" count="48"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="17"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="34"/>
                <participants group_id="P2" count="60"/>
                <participants group_id="P3" count="66"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Sponsor terminated study</title>
              <participants_list>
                <participants group_id="P1" count="89"/>
                <participants group_id="P2" count="333"/>
                <participants group_id="P3" count="330"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>AE, serious fatal</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>SAE, non-fatal</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="23"/>
                <participants group_id="P3" count="14"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>AE, non-serious non-fatal</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="19"/>
                <participants group_id="P3" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>SAE, non-fatal+AE, non-serious non-fatal</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>AE, unknown type</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="16"/>
                <participants group_id="P3" count="18"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Baseline Characteristics refers to the Enrolled Set, that consisted of all subjects who gave informed consent.</population>
      <group_list>
        <group group_id="B1">
          <title>Enrollment Cohort 1 Epratuzumab 600 mg Per Week (ES)</title>
          <description>Enrolled Set (ES) of subjects enrolled prior to the approval of Protocol Amendment 2. 600 mg infusions delivered weekly for a total of 4 consecutive weeks (cumulative dose 2400 mg) over sixteen 12-week treatment cycles</description>
        </group>
        <group group_id="B2">
          <title>Enrollment Cohort 2 Epratuzumab 1200 mg Q2W (ES)</title>
          <description>Enrolled Set (ES) of subjects enrolled prior to the approval of Protocol Amendment 2
1200 mg infusions delivered every other week (Q2W) for a total of 4 weeks (cumulative dose 2400 mg) over sixteen 12 week treatment cycles</description>
        </group>
        <group group_id="B3">
          <title>Enrollment Cohort 2 Epratuzumab 600 mg Per Week (ES)</title>
          <description>Enrolled Set (ES) of subjects enrolled prior to the approval of Protocol Amendment 2
600 mg infusions delivered weekly for a total of 4 consecutive weeks (cumulative dose 2400 mg) over sixteen 12-week treatment cycles</description>
        </group>
        <group group_id="B4">
          <title>Total Title</title>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="244"/>
            <count group_id="B2" value="498"/>
            <count group_id="B3" value="508"/>
            <count group_id="B4" value="1250"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="239"/>
                    <measurement group_id="B2" value="489"/>
                    <measurement group_id="B3" value="490"/>
                    <measurement group_id="B4" value="1218"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="18"/>
                    <measurement group_id="B4" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41.0" spread="12.0"/>
                    <measurement group_id="B2" value="41.9" spread="11.5"/>
                    <measurement group_id="B3" value="42.5" spread="11.9"/>
                    <measurement group_id="B4" value="42.0" spread="11.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="226"/>
                    <measurement group_id="B2" value="467"/>
                    <measurement group_id="B3" value="478"/>
                    <measurement group_id="B4" value="1171"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="30"/>
                    <measurement group_id="B4" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects Prematurely Discontinuing Due to a Treatment-emergent Adverse Event (TEAE) During the Treatment Period (Maximum 96 Weeks)</title>
        <description>A TEAE is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment.</description>
        <time_frame>During the treatment period (through Week 96)</time_frame>
        <population>Safety Set (SS) which consisted of all subjects who had received at least 1 partial dose of study medication during SL0012. A partial dose of study medication was defined as any infusion during which the subject received more than (&gt;) 0mL of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Enrollment Cohort 1 Epratuzumab 600 mg Per Week (ES)</title>
            <description>Enrolled Set (ES) of subjects enrolled prior to the approval of Protocol Amendment 2. 600 mg infusions delivered weekly for a total of 4 consecutive weeks (cumulative dose 2400 mg) over sixteen 12-week treatment cycles</description>
          </group>
          <group group_id="O2">
            <title>Enrollment Cohort 2 Epratuzumab 1200 mg Q2W (ES)</title>
            <description>Enrolled Set (ES) of subjects enrolled prior to the approval of Protocol Amendment 2
1200 mg infusions delivered every other week (Q2W) for a total of 4 weeks (cumulative dose 2400 mg) over sixteen 12 week treatment cycles</description>
          </group>
          <group group_id="O3">
            <title>Enrollment Cohort 2 Epratuzumab 600 mg Per Week (ES)</title>
            <description>Enrolled Set (ES) of subjects enrolled prior to the approval of Protocol Amendment 2
600 mg infusions delivered weekly for a total of 4 consecutive weeks (cumulative dose 2400 mg) over sixteen 12-week treatment cycles</description>
          </group>
          <group group_id="O4">
            <title>All Epratuzumab 600 mg Per Week</title>
            <description>600 mg infusions delivered weekly for a total of 4 consecutive weeks (cumulative dose 2400 mg) over sixteen 12-week treatment cycles</description>
          </group>
          <group group_id="O5">
            <title>All Subjects</title>
            <description>Subjects receiving 600 mg infusions delivered weekly for a total of 4 consecutive weeks (cumulative dose 2400 mg) over sixteen 12-week treatment cycles and subjects receiving 1200 mg infusions delivered every other week for a total of 4 weeks (cumulative dose 2400 mg) over sixteen 12 week treatment cycles</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Prematurely Discontinuing Due to a Treatment-emergent Adverse Event (TEAE) During the Treatment Period (Maximum 96 Weeks)</title>
          <description>A TEAE is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment.</description>
          <population>Safety Set (SS) which consisted of all subjects who had received at least 1 partial dose of study medication during SL0012. A partial dose of study medication was defined as any infusion during which the subject received more than (&gt;) 0mL of study medication.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="244"/>
                <count group_id="O2" value="497"/>
                <count group_id="O3" value="507"/>
                <count group_id="O4" value="751"/>
                <count group_id="O5" value="1248"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="45"/>
                    <measurement group_id="O3" value="25"/>
                    <measurement group_id="O4" value="51"/>
                    <measurement group_id="O5" value="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Subjects Prematurely Discontinuing Due to a Treatment-emergent Adverse Event (TEAE) During the Treatment Period (Maximum 96 Weeks)</title>
        <description>A TEAE is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment.</description>
        <time_frame>During the treatment period (through Week 96)</time_frame>
        <population>Safety Set (SS) which consisted of all subjects who had received at least 1 partial dose of study medication during SL0012. A partial dose of study medication was defined as any infusion during which the subject received &gt;0mL of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Enrollment Cohort 1 Epratuzumab 600 mg Per Week</title>
            <description>Subjects enrolled prior to the approval of Protocol Amendment 2. 600 mg infusions delivered weekly for a total of 4 consecutive weeks (cumulative dose 2400 mg) over sixteen 12-week treatment cycles</description>
          </group>
          <group group_id="O2">
            <title>Enrollment Cohort 2 Epratuzumab 1200 mg Q2W</title>
            <description>Subjects enrolled after approval of Protocol Amendment 2. 1200 mg infusions delivered every other week (Q2W) for a total of 4 weeks (cumulative dose 2400 mg) over sixteen 12 week treatment cycles</description>
          </group>
          <group group_id="O3">
            <title>Enrollment Cohort 2 Epratuzumab 600 mg Per Week</title>
            <description>Subjects enrolled after approval of Protocol Amendment 2. 600 mg infusions delivered weekly for a total of 4 consecutive weeks (cumulative dose 2400 mg) over sixteen 12-week treatment cycles</description>
          </group>
          <group group_id="O4">
            <title>All Epratuzumab 600 mg Per Week</title>
            <description>600 mg infusions delivered weekly for a total of 4 consecutive weeks (cumulative dose 2400 mg) over sixteen 12-week treatment cycles</description>
          </group>
          <group group_id="O5">
            <title>All Subjects</title>
            <description>Subjects receiving 600 mg infusions delivered weekly for a total of 4 consecutive weeks (cumulative dose 2400 mg) over sixteen 12-week treatment cycles and subjects receiving 1200 mg infusions delivered every other week for a total of 4 weeks (cumulative dose 2400 mg) over sixteen 12 week treatment cycles</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects Prematurely Discontinuing Due to a Treatment-emergent Adverse Event (TEAE) During the Treatment Period (Maximum 96 Weeks)</title>
          <description>A TEAE is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment.</description>
          <population>Safety Set (SS) which consisted of all subjects who had received at least 1 partial dose of study medication during SL0012. A partial dose of study medication was defined as any infusion during which the subject received &gt;0mL of study medication.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="244"/>
                <count group_id="O2" value="497"/>
                <count group_id="O3" value="507"/>
                <count group_id="O4" value="751"/>
                <count group_id="O5" value="1248"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.7"/>
                    <measurement group_id="O2" value="9.1"/>
                    <measurement group_id="O3" value="4.9"/>
                    <measurement group_id="O4" value="6.8"/>
                    <measurement group_id="O5" value="7.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects Reporting at Least 1 Serious Adverse Event (SAE) During the Treatment Period (Maximum 96 Weeks)</title>
        <description>A SAE is a treatment-emergent adverse event (TEAE) that the investigator classifies as serious. This includes:
Death
Life-threatening
Significant or persistent disability/incapacity
Congenital anomaly/birth defect (including that occurring in a fetus)
Important medical event that, based upon appropriate medical judgment, may jeopardize the patient or subject and may require medical or surgical intervention to prevent 1 of the other outcomes listed in the definition of serious
Initial inpatient hospitalization or prolongation of hospitalization</description>
        <time_frame>During the treatment period (through Week 96)</time_frame>
        <population>Safety Set (SS) which consisted of all subjects who had received at least 1 partial dose of study medication during SL0012. A partial dose of study medication was defined as any infusion during which the subject received &gt;0mL of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Enrollment Cohort 1 Epratuzumab 600 mg Per Week</title>
            <description>Subjects enrolled prior to the approval of Protocol Amendment 2. 600 mg infusions delivered weekly for a total of 4 consecutive weeks (cumulative dose 2400 mg) over sixteen 12-week treatment cycles</description>
          </group>
          <group group_id="O2">
            <title>Enrollment Cohort 2 Epratuzumab 1200 mg Q2W</title>
            <description>Subjects enrolled after approval of Protocol Amendment 2. 1200 mg infusions delivered every other week (Q2W) for a total of 4 weeks (cumulative dose 2400 mg) over sixteen 12 week treatment cycles</description>
          </group>
          <group group_id="O3">
            <title>Enrollment Cohort 2 Epratuzumab 600 mg Per Week</title>
            <description>Subjects enrolled after approval of Protocol Amendment 2. 600 mg infusions delivered weekly for a total of 4 consecutive weeks (cumulative dose 2400 mg) over sixteen 12-week treatment cycles</description>
          </group>
          <group group_id="O4">
            <title>All Epratuzumab 600 mg Per Week</title>
            <description>600 mg infusions delivered weekly for a total of 4 consecutive weeks (cumulative dose 2400 mg) over sixteen 12-week treatment cycles</description>
          </group>
          <group group_id="O5">
            <title>All Subjects</title>
            <description>Subjects receiving 600 mg infusions delivered weekly for a total of 4 consecutive weeks (cumulative dose 2400 mg) over sixteen 12-week treatment cycles and subjects receiving 1200 mg infusions delivered every other week for a total of 4 weeks (cumulative dose 2400 mg) over sixteen 12 week treatment cycles</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting at Least 1 Serious Adverse Event (SAE) During the Treatment Period (Maximum 96 Weeks)</title>
          <description>A SAE is a treatment-emergent adverse event (TEAE) that the investigator classifies as serious. This includes:
Death
Life-threatening
Significant or persistent disability/incapacity
Congenital anomaly/birth defect (including that occurring in a fetus)
Important medical event that, based upon appropriate medical judgment, may jeopardize the patient or subject and may require medical or surgical intervention to prevent 1 of the other outcomes listed in the definition of serious
Initial inpatient hospitalization or prolongation of hospitalization</description>
          <population>Safety Set (SS) which consisted of all subjects who had received at least 1 partial dose of study medication during SL0012. A partial dose of study medication was defined as any infusion during which the subject received &gt;0mL of study medication.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="244"/>
                <count group_id="O2" value="497"/>
                <count group_id="O3" value="507"/>
                <count group_id="O4" value="751"/>
                <count group_id="O5" value="1248"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81"/>
                    <measurement group_id="O2" value="119"/>
                    <measurement group_id="O3" value="104"/>
                    <measurement group_id="O4" value="185"/>
                    <measurement group_id="O5" value="304"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Subjects Reporting at Least 1 Serious Adverse Event (SAE) During the Treatment Period (Maximum 96 Weeks)</title>
        <description>A SAE is a treatment-emergent adverse event (TEAE) that the investigator classifies as serious. This includes:
Death
Life-threatening
Significant or persistent disability/incapacity
Congenital anomaly/birth defect (including that occurring in a fetus)
Important medical event that, based upon appropriate medical judgment, may jeopardize the patient or subject and may require medical or surgical intervention to prevent 1 of the other outcomes listed in the definition of serious
Initial inpatient hospitalization or prolongation of hospitalization</description>
        <time_frame>During the treatment period (through Week 96)</time_frame>
        <population>Safety Set (SS) which consisted of all subjects who had received at least 1 partial dose of study medication during SL0012. A partial dose of study medication was defined as any infusion during which the subject received &gt;0mL of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Enrollment Cohort 1 Epratuzumab 600 mg Per Week</title>
            <description>Subjects enrolled prior to the approval of Protocol Amendment 2. 600 mg infusions delivered weekly for a total of 4 consecutive weeks (cumulative dose 2400 mg) over sixteen 12-week treatment cycles</description>
          </group>
          <group group_id="O2">
            <title>Enrollment Cohort 2 Epratuzumab 1200 mg Q2W</title>
            <description>Subjects enrolled after approval of Protocol Amendment 2. 1200 mg infusions delivered every other week (Q2W) for a total of 4 weeks (cumulative dose 2400 mg) over sixteen 12 week treatment cycles</description>
          </group>
          <group group_id="O3">
            <title>Enrollment Cohort 2 Epratuzumab 600 mg Per Week</title>
            <description>Subjects enrolled after approval of Protocol Amendment 2. 600 mg infusions delivered weekly for a total of 4 consecutive weeks (cumulative dose 2400 mg) over sixteen 12-week treatment cycles</description>
          </group>
          <group group_id="O4">
            <title>All Epratuzumab 600 mg Per Week</title>
            <description>600 mg infusions delivered weekly for a total of 4 consecutive weeks (cumulative dose 2400 mg) over sixteen 12-week treatment cycles</description>
          </group>
          <group group_id="O5">
            <title>All Subjects</title>
            <description>Subjects receiving 600 mg infusions delivered weekly for a total of 4 consecutive weeks (cumulative dose 2400 mg) over sixteen 12-week treatment cycles and subjects receiving 1200 mg infusions delivered every other week for a total of 4 weeks (cumulative dose 2400 mg) over sixteen 12 week treatment cycles</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects Reporting at Least 1 Serious Adverse Event (SAE) During the Treatment Period (Maximum 96 Weeks)</title>
          <description>A SAE is a treatment-emergent adverse event (TEAE) that the investigator classifies as serious. This includes:
Death
Life-threatening
Significant or persistent disability/incapacity
Congenital anomaly/birth defect (including that occurring in a fetus)
Important medical event that, based upon appropriate medical judgment, may jeopardize the patient or subject and may require medical or surgical intervention to prevent 1 of the other outcomes listed in the definition of serious
Initial inpatient hospitalization or prolongation of hospitalization</description>
          <population>Safety Set (SS) which consisted of all subjects who had received at least 1 partial dose of study medication during SL0012. A partial dose of study medication was defined as any infusion during which the subject received &gt;0mL of study medication.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="244"/>
                <count group_id="O2" value="497"/>
                <count group_id="O3" value="507"/>
                <count group_id="O4" value="751"/>
                <count group_id="O5" value="1248"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.2"/>
                    <measurement group_id="O2" value="23.9"/>
                    <measurement group_id="O3" value="20.5"/>
                    <measurement group_id="O4" value="24.6"/>
                    <measurement group_id="O5" value="24.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Meeting Treatment Response Criteria According to a Combined Response Index</title>
        <description>Combined response index is a response variable (yes/no) incorporating the following criteria for achievement of responder status (ie, all criteria must be met to achieve responder status): (1) British Isles Lupus Activity Group (BILAG) improvement, (2) No worsening in Systemic Lupus Erythematosus Activity Index (SLEDAI), (3) No worsening in Physician's Global Assessment of Disease, and (4) No disallowed changes in concomitant medications, with disallowed changes including mainly increases in corticosteroids, immunosuppressants, and antimalarials.</description>
        <time_frame>At Week 48</time_frame>
        <population>The Full Analysis Subset 1 (FASS1) consisted of all subjects in the FAS who were enrolled in study SL0008 (NCT00660881), SL0009 (NCT01262365) or SL0010 (NCT01261793) prior to enrollment in SL0012.</population>
        <group_list>
          <group group_id="O1">
            <title>Enrollment Cohort 1 Epratuzumab 600 mg Per Week (FASS1)</title>
            <description>Full Analysis Subset 1 (FASS1) consisted of all subjects in the FAS who were enrolled in study SL0008 (NCT00660881), SL0009 (NCT01262365), or SL0010 (NCT01261793) prior to enrollment in SL0012.
Subjects were enrolled prior to the approval of Protocol Amendment 2. 600 mg infusions delivered weekly for a total of 4 consecutive weeks (cumulative dose 2400 mg) over sixteen 12-week treatment cycles</description>
          </group>
          <group group_id="O2">
            <title>Enrollment Cohort 2 Epratuzumab 1200 mg Q2W (FASS1)</title>
            <description>Full Analysis Subset 1 (FASS1) consisted of all subjects in the FAS who were enrolled in study SL0008 (NCT00660881), SL0009 (NCT01262365), or SL0010 (NCT01261793) prior to enrollment in SL0012.
Subjects were enrolled prior to the approval of Protocol Amendment 2. 1200 mg infusions delivered every other week (Q2W) for a total of 4 weeks (cumulative dose 2400 mg) over sixteen 12 week treatment cycles</description>
          </group>
          <group group_id="O3">
            <title>Enrollment Cohort 2 Epratuzumab 600 mg Per Week (FASS1)</title>
            <description>Full Analysis Subset 1 (FASS1) consisted of all subjects in the FAS who were enrolled in study SL0008 (NCT00660881), SL0009 (NCT01262365), or SL0010 (NCT01261793) prior to enrollment in SL0012.
Subjects were enrolled prior to the approval of Protocol Amendment 2. 600 mg infusions delivered weekly for a total of 4 consecutive weeks (cumulative dose 2400 mg) over sixteen 12-week treatment cycles</description>
          </group>
          <group group_id="O4">
            <title>All Epratuzumab 600 mg Per Week (FASS1)</title>
            <description>Full Analysis Subset 1 (FASS1) consisted of all subjects in the FAS who were enrolled in study SL0008 (NCT00660881), SL0009 (NCT01262365), or SL0010 (NCT01261793) prior to enrollment in SL0012.
Subjects were enrolled prior to the approval of Protocol Amendment 2. 600 mg infusions delivered weekly for a total of 4 consecutive weeks (cumulative dose 2400 mg) over sixteen 12-week treatment cycles</description>
          </group>
          <group group_id="O5">
            <title>All Subjects (FASS1)</title>
            <description>Full Analysis Subset 1 (FASS1) consisted of all subjects in the FAS who were enrolled in study SL0008 (NCT00660881), SL0009 (NCT01262365), or SL0010 (NCT01261793) prior to enrollment in SL0012.
Subjects were enrolled prior to the approval of Protocol Amendment 2. Subjects receiving 600 mg infusions delivered weekly for a total of 4 consecutive weeks (cumulative dose 2400 mg) over sixteen 12-week treatment cycles and subjects receiving 1200 mg infusions delivered every other week for a total of 4 weeks (cumulative dose 2400 mg) over sixteen 12 week treatment cycles</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Meeting Treatment Response Criteria According to a Combined Response Index</title>
          <description>Combined response index is a response variable (yes/no) incorporating the following criteria for achievement of responder status (ie, all criteria must be met to achieve responder status): (1) British Isles Lupus Activity Group (BILAG) improvement, (2) No worsening in Systemic Lupus Erythematosus Activity Index (SLEDAI), (3) No worsening in Physician's Global Assessment of Disease, and (4) No disallowed changes in concomitant medications, with disallowed changes including mainly increases in corticosteroids, immunosuppressants, and antimalarials.</description>
          <population>The Full Analysis Subset 1 (FASS1) consisted of all subjects in the FAS who were enrolled in study SL0008 (NCT00660881), SL0009 (NCT01262365) or SL0010 (NCT01261793) prior to enrollment in SL0012.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="230"/>
                <count group_id="O2" value="488"/>
                <count group_id="O3" value="494"/>
                <count group_id="O4" value="724"/>
                <count group_id="O5" value="1212"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82"/>
                    <measurement group_id="O2" value="146"/>
                    <measurement group_id="O3" value="134"/>
                    <measurement group_id="O4" value="216"/>
                    <measurement group_id="O5" value="362"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects Meeting Treatment Response Criteria According to a Combined Response Index</title>
        <description>Combined response index is a response variable (yes/no) incorporating the following criteria for achievement of responder status (ie, all criteria must be met to achieve responder status): (1) British Isles Lupus Activity Group (BILAG) improvement, (2) No worsening in Systemic Lupus Erythematosus Activity Index (SLEDAI), (3) No worsening in Physician's Global Assessment of Disease, and (4) No disallowed changes in concomitant medications, with disallowed changes including mainly increases in corticosteroids, immunosuppressants, and antimalarials.</description>
        <time_frame>Week 48</time_frame>
        <population>The Full Analysis Subset 1 (FASS1) consisted of all subjects in the FAS who were enrolled in study SL0008 (NCT00660881), SL0009 (NCT01262365) or SL0010 (NCT01261793) prior to enrollment in SL0012.</population>
        <group_list>
          <group group_id="O1">
            <title>Enrollment Cohort 1 Epratuzumab 600 mg Per Week (FASS1)</title>
            <description>Full Analysis Subset 1 (FASS1) consisted of all subjects in the FAS who were enrolled in study SL0008 (NCT00660881), SL0009 (NCT01262365), or SL0010 (NCT01261793) prior to enrollment in SL0012.
Subjects were enrolled prior to the approval of Protocol Amendment 2. 600 mg infusions delivered weekly for a total of 4 consecutive weeks (cumulative dose 2400 mg) over sixteen 12-week treatment cycles</description>
          </group>
          <group group_id="O2">
            <title>Enrollment Cohort 2 Epratuzumab 1200 mg Q2W (FASS1)</title>
            <description>Full Analysis Subset 1 (FASS1) consisted of all subjects in the FAS who were enrolled in study SL0008 (NCT00660881), SL0009 (NCT01262365), or SL0010 (NCT01261793) prior to enrollment in SL0012.
Subjects were enrolled prior to the approval of Protocol Amendment 2. 1200 mg infusions delivered every other week (Q2W) for a total of 4 weeks (cumulative dose 2400 mg) over sixteen 12 week treatment cycles</description>
          </group>
          <group group_id="O3">
            <title>Enrollment Cohort 2 Epratuzumab 600 mg Per Week (FASS1)</title>
            <description>Full Analysis Subset 1 (FASS1) consisted of all subjects in the FAS who were enrolled in study SL0008 (NCT00660881), SL0009 (NCT01262365), or SL0010 (NCT01261793) prior to enrollment in SL0012.
Subjects were enrolled prior to the approval of Protocol Amendment 2. 600 mg infusions delivered weekly for a total of 4 consecutive weeks (cumulative dose 2400 mg) over sixteen 12-week treatment cycles</description>
          </group>
          <group group_id="O4">
            <title>All Epratuzumab 600 mg Per Week (FASS1)</title>
            <description>Full Analysis Subset 1 (FASS1) consisted of all subjects in the FAS who were enrolled in study SL0008 (NCT00660881), SL0009 (NCT01262365), or SL0010 (NCT01261793) prior to enrollment in SL0012.
Subjects were enrolled prior to the approval of Protocol Amendment 2. 600 mg infusions delivered weekly for a total of 4 consecutive weeks (cumulative dose 2400 mg) over sixteen 12-week treatment cycles</description>
          </group>
          <group group_id="O5">
            <title>All Subjects (FASS1)</title>
            <description>Full Analysis Subset 1 (FASS1) consisted of all subjects in the FAS who were enrolled in study SL0008 (NCT00660881), SL0009 (NCT01262365), or SL0010 (NCT01261793) prior to enrollment in SL0012.
Subjects were enrolled prior to the approval of Protocol Amendment 2. Subjects receiving 600 mg infusions delivered weekly for a total of 4 consecutive weeks (cumulative dose 2400 mg) over sixteen 12-week treatment cycles and subjects receiving 1200 mg infusions delivered every other week for a total of 4 weeks (cumulative dose 2400 mg) over sixteen 12 week treatment cycles</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects Meeting Treatment Response Criteria According to a Combined Response Index</title>
          <description>Combined response index is a response variable (yes/no) incorporating the following criteria for achievement of responder status (ie, all criteria must be met to achieve responder status): (1) British Isles Lupus Activity Group (BILAG) improvement, (2) No worsening in Systemic Lupus Erythematosus Activity Index (SLEDAI), (3) No worsening in Physician's Global Assessment of Disease, and (4) No disallowed changes in concomitant medications, with disallowed changes including mainly increases in corticosteroids, immunosuppressants, and antimalarials.</description>
          <population>The Full Analysis Subset 1 (FASS1) consisted of all subjects in the FAS who were enrolled in study SL0008 (NCT00660881), SL0009 (NCT01262365) or SL0010 (NCT01261793) prior to enrollment in SL0012.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="230"/>
                <count group_id="O2" value="488"/>
                <count group_id="O3" value="494"/>
                <count group_id="O4" value="724"/>
                <count group_id="O5" value="1212"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.7"/>
                    <measurement group_id="O2" value="29.9"/>
                    <measurement group_id="O3" value="27.1"/>
                    <measurement group_id="O4" value="29.8"/>
                    <measurement group_id="O5" value="29.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Meeting Treatment Response Criteria According to a Combined Response Index</title>
        <description>Combined response index is a response variable (yes/no) incorporating the following criteria for achievement of responder status (ie, all criteria must be met to achieve responder status): (1) British Isles Lupus Activity Group (BILAG) improvement, (2) No worsening in Systemic Lupus Erythematosus Activity Index (SLEDAI), (3) No worsening in Physician's Global Assessment of Disease, and (4) No disallowed changes in concomitant medications, with disallowed changes including mainly increases in corticosteroids, immunosuppressants, and antimalarials.</description>
        <time_frame>Week 96</time_frame>
        <population>The Full Analysis Subset 1 (FASS1) consisted of all subjects in the FAS who were enrolled in study SL0008 (NCT00660881), SL0009 (NCT01262365) or SL0010 (NCT01261793) prior to enrollment in SL0012, and with available results at the Week 96 time-point.</population>
        <group_list>
          <group group_id="O1">
            <title>Enrollment Cohort 1 Epratuzumab 600 mg Per Week (FASS1)</title>
            <description>Full Analysis Subset 1 (FASS1) consisted of all subjects in the FAS who were enrolled in study SL0008 (NCT00660881), SL0009 (NCT01262365), or SL0010 (NCT01261793) prior to enrollment in SL0012.
Subjects were enrolled prior to the approval of Protocol Amendment 2. 600 mg infusions delivered weekly for a total of 4 consecutive weeks (cumulative dose 2400 mg) over sixteen 12-week treatment cycles</description>
          </group>
          <group group_id="O2">
            <title>Enrollment Cohort 2 Epratuzumab 1200 mg Q2W (FASS1)</title>
            <description>Full Analysis Subset 1 (FASS1) consisted of all subjects in the FAS who were enrolled in study SL0008 (NCT00660881), SL0009 (NCT01262365), or SL0010 (NCT01261793) prior to enrollment in SL0012.
Subjects were enrolled prior to the approval of Protocol Amendment 2. 1200 mg infusions delivered every other week (Q2W) for a total of 4 weeks (cumulative dose 2400 mg) over sixteen 12 week treatment cycles</description>
          </group>
          <group group_id="O3">
            <title>Enrollment Cohort 2 Epratuzumab 600 mg Per Week (FASS1)</title>
            <description>Full Analysis Subset 1 (FASS1) consisted of all subjects in the FAS who were enrolled in study SL0008 (NCT00660881), SL0009 (NCT01262365), or SL0010 (NCT01261793) prior to enrollment in SL0012.
Subjects were enrolled prior to the approval of Protocol Amendment 2. 600 mg infusions delivered weekly for a total of 4 consecutive weeks (cumulative dose 2400 mg) over sixteen 12-week treatment cycles</description>
          </group>
          <group group_id="O4">
            <title>All Epratuzumab 600 mg Per Week (FASS1)</title>
            <description>Full Analysis Subset 1 (FASS1) consisted of all subjects in the FAS who were enrolled in study SL0008 (NCT00660881), SL0009 (NCT01262365), or SL0010 (NCT01261793) prior to enrollment in SL0012.
Subjects were enrolled prior to the approval of Protocol Amendment 2. 600 mg infusions delivered weekly for a total of 4 consecutive weeks (cumulative dose 2400 mg) over sixteen 12-week treatment cycles</description>
          </group>
          <group group_id="O5">
            <title>All Subjects (FASS1)</title>
            <description>Full Analysis Subset 1 (FASS1) consisted of all subjects in the FAS who were enrolled in study SL0008 (NCT00660881), SL0009 (NCT01262365), or SL0010 (NCT01261793) prior to enrollment in SL0012.
Subjects were enrolled prior to the approval of Protocol Amendment 2. Subjects receiving 600 mg infusions delivered weekly for a total of 4 consecutive weeks (cumulative dose 2400 mg) over sixteen 12-week treatment cycles and subjects receiving 1200 mg infusions delivered every other week for a total of 4 weeks (cumulative dose 2400 mg) over sixteen 12 week treatment cycles</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Meeting Treatment Response Criteria According to a Combined Response Index</title>
          <description>Combined response index is a response variable (yes/no) incorporating the following criteria for achievement of responder status (ie, all criteria must be met to achieve responder status): (1) British Isles Lupus Activity Group (BILAG) improvement, (2) No worsening in Systemic Lupus Erythematosus Activity Index (SLEDAI), (3) No worsening in Physician's Global Assessment of Disease, and (4) No disallowed changes in concomitant medications, with disallowed changes including mainly increases in corticosteroids, immunosuppressants, and antimalarials.</description>
          <population>The Full Analysis Subset 1 (FASS1) consisted of all subjects in the FAS who were enrolled in study SL0008 (NCT00660881), SL0009 (NCT01262365) or SL0010 (NCT01261793) prior to enrollment in SL0012, and with available results at the Week 96 time-point.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="186"/>
                <count group_id="O2" value="306"/>
                <count group_id="O3" value="298"/>
                <count group_id="O4" value="484"/>
                <count group_id="O5" value="790"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74"/>
                    <measurement group_id="O2" value="66"/>
                    <measurement group_id="O3" value="78"/>
                    <measurement group_id="O4" value="152"/>
                    <measurement group_id="O5" value="218"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Percent of Subjects Meeting Treatment Response Criteria According to a Combined Response Index</title>
        <description>Combined response index is a response variable (yes/no) incorporating the following criteria for achievement of responder status (ie, all criteria must be met to achieve responder status): (1) British Isles Lupus Activity Group (BILAG) improvement, (2) No worsening in Systemic Lupus Erythematosus Activity Index (SLEDAI), (3) No worsening in Physician's Global Assessment of Disease, and (4) No disallowed changes in concomitant medications, with disallowed changes including mainly increases in corticosteroids, immunosuppressants, and antimalarials.</description>
        <time_frame>Week 96</time_frame>
        <population>The Full Analysis Subset 1 (FASS1) consisted of all subjects in the FAS who were enrolled in study SL0008 (NCT00660881), SL0009 (NCT01262365) or SL0010 (NCT01261793) prior to enrollment in SL0012, and with available results at the Week 96 time-point.</population>
        <group_list>
          <group group_id="O1">
            <title>Enrollment Cohort 1 Epratuzumab 600 mg Per Week (FASS1)</title>
            <description>Full Analysis Subset 1 (FASS1) consisted of all subjects in the FAS who were enrolled in study SL0008 (NCT00660881), SL0009 (NCT01262365), or SL0010 (NCT01261793) prior to enrollment in SL0012.
Subjects were enrolled prior to the approval of Protocol Amendment 2. 600 mg infusions delivered weekly for a total of 4 consecutive weeks (cumulative dose 2400 mg) over sixteen 12-week treatment cycles</description>
          </group>
          <group group_id="O2">
            <title>Enrollment Cohort 2 Epratuzumab 1200 mg Q2W (FASS1)</title>
            <description>Full Analysis Subset 1 (FASS1) consisted of all subjects in the FAS who were enrolled in study SL0008 (NCT00660881), SL0009 (NCT01262365), or SL0010 (NCT01261793) prior to enrollment in SL0012.
Subjects were enrolled prior to the approval of Protocol Amendment 2. 1200 mg infusions delivered every other week (Q2W) for a total of 4 weeks (cumulative dose 2400 mg) over sixteen 12 week treatment cycles</description>
          </group>
          <group group_id="O3">
            <title>Enrollment Cohort 2 Epratuzumab 600 mg Per Week (FASS1)</title>
            <description>Full Analysis Subset 1 (FASS1) consisted of all subjects in the FAS who were enrolled in study SL0008 (NCT00660881), SL0009 (NCT01262365), or SL0010 (NCT01261793) prior to enrollment in SL0012.
Subjects were enrolled prior to the approval of Protocol Amendment 2. 600 mg infusions delivered weekly for a total of 4 consecutive weeks (cumulative dose 2400 mg) over sixteen 12-week treatment cycles</description>
          </group>
          <group group_id="O4">
            <title>All Epratuzumab 600 mg Per Week (FASS1)</title>
            <description>Full Analysis Subset 1 (FASS1) consisted of all subjects in the FAS who were enrolled in study SL0008 (NCT00660881), SL0009 (NCT01262365), or SL0010 (NCT01261793) prior to enrollment in SL0012.
Subjects were enrolled prior to the approval of Protocol Amendment 2. 600 mg infusions delivered weekly for a total of 4 consecutive weeks (cumulative dose 2400 mg) over sixteen 12-week treatment cycles</description>
          </group>
          <group group_id="O5">
            <title>All Subjects (FASS1)</title>
            <description>Full Analysis Subset 1 (FASS1) consisted of all subjects in the FAS who were enrolled in study SL0008 (NCT00660881), SL0009 (NCT01262365), or SL0010 (NCT01261793) prior to enrollment in SL0012.
Subjects were enrolled prior to the approval of Protocol Amendment 2. Subjects receiving 600 mg infusions delivered weekly for a total of 4 consecutive weeks (cumulative dose 2400 mg) over sixteen 12-week treatment cycles and subjects receiving 1200 mg infusions delivered every other week for a total of 4 weeks (cumulative dose 2400 mg) over sixteen 12 week treatment cycles</description>
          </group>
        </group_list>
        <measure>
          <title>The Percent of Subjects Meeting Treatment Response Criteria According to a Combined Response Index</title>
          <description>Combined response index is a response variable (yes/no) incorporating the following criteria for achievement of responder status (ie, all criteria must be met to achieve responder status): (1) British Isles Lupus Activity Group (BILAG) improvement, (2) No worsening in Systemic Lupus Erythematosus Activity Index (SLEDAI), (3) No worsening in Physician's Global Assessment of Disease, and (4) No disallowed changes in concomitant medications, with disallowed changes including mainly increases in corticosteroids, immunosuppressants, and antimalarials.</description>
          <population>The Full Analysis Subset 1 (FASS1) consisted of all subjects in the FAS who were enrolled in study SL0008 (NCT00660881), SL0009 (NCT01262365) or SL0010 (NCT01261793) prior to enrollment in SL0012, and with available results at the Week 96 time-point.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="186"/>
                <count group_id="O2" value="306"/>
                <count group_id="O3" value="298"/>
                <count group_id="O4" value="484"/>
                <count group_id="O5" value="790"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.8"/>
                    <measurement group_id="O2" value="21.6"/>
                    <measurement group_id="O3" value="26.2"/>
                    <measurement group_id="O4" value="31.4"/>
                    <measurement group_id="O5" value="27.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected from Visit 1 until Safety Follow-Up Visit (up to Week 196)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Enrollment Cohort 1 Epratuzumab 600 mg Per Week</title>
          <description>Subjects enrolled prior to the approval of Protocol Amendment 2. 600 mg infusions delivered weekly for a total of 4 consecutive weeks (cumulative dose 2400 mg) over sixteen 12-week treatment cycles</description>
        </group>
        <group group_id="E2">
          <title>Enrollment Cohort 2 Epratuzumab 1200 mg Q2W</title>
          <description>Subjects enrolled after approval of Protocol Amendment 2. 1200 mg infusions delivered every other week (Q2W) for a total of 4 weeks (cumulative dose 2400 mg) over sixteen 12 week treatment cycles</description>
        </group>
        <group group_id="E3">
          <title>Enrollment Cohort 2 Epratuzumab 600 mg Per Week</title>
          <description>Subjects enrolled after approval of Protocol Amendment 2. 600 mg infusions delivered weekly for a total of 4 consecutive weeks (cumulative dose 2400 mg) over sixteen 12-week treatment cycles</description>
        </group>
        <group group_id="E4">
          <title>All Epratuzumab 600 mg Per Week</title>
          <description>600 mg infusions delivered weekly for a total of 4 consecutive weeks (cumulative dose 2400 mg) over sixteen 12-week treatment cycles</description>
        </group>
        <group group_id="E5">
          <title>All Subjects</title>
          <description>Subjects receiving 600 mg infusions delivered weekly for a total of 4 consecutive weeks (cumulative dose 2400 mg) over sixteen 12-week treatment cycles and subjects receiving 1200 mg infusions delivered every other week for a total of 4 weeks (cumulative dose 2400 mg) over sixteen 12 week treatment cycles</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA17.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="244"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="497"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="751"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="81" subjects_at_risk="244"/>
                <counts group_id="E2" subjects_affected="119" subjects_at_risk="497"/>
                <counts group_id="E3" subjects_affected="104" subjects_at_risk="507"/>
                <counts group_id="E4" subjects_affected="185" subjects_at_risk="751"/>
                <counts group_id="E5" subjects_affected="304" subjects_at_risk="1248"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="497"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E4" events="3" subjects_affected="2" subjects_at_risk="751"/>
                <counts group_id="E5" events="5" subjects_affected="4" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="497"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="507"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="751"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="497"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="751"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="497"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="507"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="751"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Eosinophilia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="497"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="751"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Haemorrhagic diathesis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="497"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="751"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="497"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="751"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="497"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="751"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Splenic cyst</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="497"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="751"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1248"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="497"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="751"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Pericarditis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="497"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="751"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="497"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="751"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="497"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="751"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Atrioventricular block complete</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="497"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="751"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="497"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="751"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="497"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="751"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Pleuropericarditis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="497"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="751"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Sinoatrial block</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="497"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="751"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="497"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="751"/>
                <counts group_id="E5" events="2" subjects_affected="1" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="497"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="751"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="497"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="751"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1248"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Factor VII deficiency</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="497"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="751"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1248"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="497"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="751"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1248"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Adrenal insufficiency</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="497"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="751"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Toxic nodular goitre</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="497"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="751"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1248"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="497"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="751"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Amaurosis fugax</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="497"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="751"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Necrotising retinitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="497"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="751"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Panophthalmitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="497"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="751"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Retinal disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="497"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="751"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1248"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="497"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="507"/>
                <counts group_id="E4" events="5" subjects_affected="4" subjects_at_risk="751"/>
                <counts group_id="E5" events="8" subjects_affected="7" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="497"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="507"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="751"/>
                <counts group_id="E5" events="6" subjects_affected="6" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="497"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="751"/>
                <counts group_id="E5" events="5" subjects_affected="5" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="497"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E4" events="4" subjects_affected="3" subjects_at_risk="751"/>
                <counts group_id="E5" events="5" subjects_affected="4" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="497"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="751"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="497"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="751"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="497"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="751"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="497"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="751"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="497"/>
                <counts group_id="E3" events="3" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E4" events="3" subjects_affected="1" subjects_at_risk="751"/>
                <counts group_id="E5" events="4" subjects_affected="2" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Anal fissure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="497"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="751"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="497"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="751"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Colitis ischaemic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="497"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="751"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="497"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="751"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Crohn's disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="497"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="751"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Eosinophilic colitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="497"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="751"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Gastritis haemorrhagic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="497"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="751"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="497"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="751"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="497"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="751"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Hiatus hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="497"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="751"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Impaired gastric emptying</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="497"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="751"/>
                <counts group_id="E5" events="2" subjects_affected="1" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Inflammatory bowel disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="497"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="751"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="497"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="751"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Oedematous pancreatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="497"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="751"/>
                <counts group_id="E5" events="2" subjects_affected="1" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Oesophageal disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="497"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="751"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Oesophageal motility disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="497"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="751"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Oesophageal spasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="497"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="751"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Peptic ulcer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="497"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="751"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Peritoneal haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="497"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="751"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Salivary gland calculus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="497"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="751"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Subileus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="497"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="751"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1248"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="497"/>
                <counts group_id="E3" events="9" subjects_affected="8" subjects_at_risk="507"/>
                <counts group_id="E4" events="10" subjects_affected="9" subjects_at_risk="751"/>
                <counts group_id="E5" events="14" subjects_affected="13" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="244"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="497"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="751"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="497"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="751"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="497"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="751"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Drug interaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="497"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="751"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Drug intolerance</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="497"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="751"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Hyperthermia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="497"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="751"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Impaired healing</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="497"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="751"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Local swelling</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="497"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="751"/>
                <counts group_id="E5" events="2" subjects_affected="1" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="497"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="751"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Serositis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="497"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="751"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1248"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="244"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="497"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="751"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="497"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="507"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="751"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Bile duct stone</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="497"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="507"/>
                <counts group_id="E4" events="3" subjects_affected="2" subjects_at_risk="751"/>
                <counts group_id="E5" events="3" subjects_affected="2" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Cholangitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="497"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="751"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="497"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="751"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Cholelithiasis migration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="497"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="751"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Hepatic steatosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="497"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="751"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1248"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="497"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="751"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Anaphylactic reaction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="497"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="751"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1248"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="244"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="497"/>
                <counts group_id="E3" events="10" subjects_affected="9" subjects_at_risk="507"/>
                <counts group_id="E4" events="16" subjects_affected="15" subjects_at_risk="751"/>
                <counts group_id="E5" events="23" subjects_affected="22" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="244"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="497"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="507"/>
                <counts group_id="E4" events="8" subjects_affected="7" subjects_at_risk="751"/>
                <counts group_id="E5" events="11" subjects_affected="10" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="497"/>
                <counts group_id="E3" events="5" subjects_affected="3" subjects_at_risk="507"/>
                <counts group_id="E4" events="6" subjects_affected="4" subjects_at_risk="751"/>
                <counts group_id="E5" events="10" subjects_affected="8" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="244"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="497"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="507"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="751"/>
                <counts group_id="E5" events="7" subjects_affected="7" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Arthritis bacterial</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="497"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="751"/>
                <counts group_id="E5" events="4" subjects_affected="3" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="497"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="751"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Gastroenteritis salmonella</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="497"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="751"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="497"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="751"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="497"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="507"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="751"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="497"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="507"/>
                <counts group_id="E4" events="3" subjects_affected="2" subjects_at_risk="751"/>
                <counts group_id="E5" events="4" subjects_affected="3" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="497"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="751"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Clostridium difficile colitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="497"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="751"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Clostridium difficile infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="497"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="751"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Meningitis viral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="497"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="751"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Subcutaneous abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="497"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="751"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="497"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="507"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="751"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="497"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="751"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Abscess limb</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="497"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="751"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Anal abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="497"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="751"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="497"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="751"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="497"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="751"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="497"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="751"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Cytomegalovirus chorioretinitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="497"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="751"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Cytomegalovirus infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="497"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="751"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Endocarditis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="497"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="751"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Epstein-Barr virus infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="497"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="751"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Escherichia bacteraemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="497"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="751"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Escherichia sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="497"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="751"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Gangrene</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="497"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="751"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>H1N1 influenza</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="497"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="751"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Haematoma infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="497"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="751"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Hepatitis B</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="497"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="751"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="497"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="751"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Lobar pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="497"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="751"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="497"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="751"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Meningitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="497"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="751"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Meningitis aseptic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="497"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="751"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Meningitis bacterial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="497"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="751"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Pelvic inflammatory disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="497"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="751"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Perineal abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="497"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="751"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Pneumonia bacterial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="497"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="751"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Pneumonia legionella</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="497"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="751"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Pneumonia streptococcal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="497"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="751"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="497"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="751"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="497"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="751"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Salpingitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="497"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="751"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Tooth abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="497"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="751"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1248"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Meniscus injury</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="497"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="751"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Tendon rupture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="497"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="507"/>
                <counts group_id="E4" events="3" subjects_affected="2" subjects_at_risk="751"/>
                <counts group_id="E5" events="4" subjects_affected="3" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="497"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="751"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Fibula fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="497"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="751"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="497"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="751"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="497"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="751"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="497"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="751"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="497"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="751"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="497"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="751"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Sternal fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="497"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="751"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Wrist fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="497"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="751"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Accidental overdose</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="497"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="751"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="497"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="751"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="497"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="751"/>
                <counts group_id="E5" events="2" subjects_affected="1" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Delayed recovery from anaesthesia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="497"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="751"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="497"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="751"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="497"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="751"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="497"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="751"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Ligament rupture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="497"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="751"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Lumbar vertebral fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="497"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="751"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Nail avulsion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="497"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="751"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="497"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="751"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Post procedural complication</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="497"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="751"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="497"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="751"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Spinal column injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="497"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="751"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Spinal fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="497"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="751"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Tendon injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="497"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="751"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="497"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="751"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="497"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="751"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1248"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Biopsy liver</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="497"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="751"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Blood cortisol decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="497"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="751"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Electrocardiogram QT prolonged</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="497"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="751"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Transaminases increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="497"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="751"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Troponin increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="497"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="751"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1248"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="497"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="507"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="751"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus inadequate control</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="497"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="751"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="497"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="751"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="497"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="751"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="497"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="751"/>
                <counts group_id="E5" events="2" subjects_affected="1" subjects_at_risk="1248"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Systemic lupus erythematosus</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="244"/>
                <counts group_id="E2" events="15" subjects_affected="13" subjects_at_risk="497"/>
                <counts group_id="E3" events="12" subjects_affected="12" subjects_at_risk="507"/>
                <counts group_id="E4" events="19" subjects_affected="19" subjects_at_risk="751"/>
                <counts group_id="E5" events="34" subjects_affected="32" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="4" subjects_affected="2" subjects_at_risk="497"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="507"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="751"/>
                <counts group_id="E5" events="7" subjects_affected="5" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="497"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="751"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="497"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="507"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="751"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Osteonecrosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="497"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="751"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="497"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="751"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Bursitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="497"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="507"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="751"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Foot deformity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="497"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="751"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Intervertebral disc disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="497"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="751"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="497"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="751"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Chondromalacia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="497"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="751"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Enthesopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="497"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="751"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Fasciitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="497"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="751"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="497"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="751"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="497"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="751"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Osteoporotic fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="497"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="751"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="497"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="751"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Patellofemoral pain syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="497"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="751"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Periarthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="497"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="751"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Rotator cuff syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="497"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="751"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>SLE arthritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="497"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="751"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Soft tissue necrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="497"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="751"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Spinal osteoarthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="497"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="751"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Spondylolisthesis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="497"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="751"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Synovial cyst</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="497"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="751"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Tenosynovitis stenosans</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="497"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="751"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1248"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Squamous cell carcinoma of skin</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="497"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="507"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="751"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Uterine leiomyoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="497"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="751"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Adenocarcinoma of colon</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="497"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="751"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Adenocarcinoma pancreas</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="497"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="751"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Bladder cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="497"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="751"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Bowen's disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="497"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="751"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Breast cancer stage I</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="497"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="751"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Cervix carcinoma stage 0</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="497"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="751"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Gastric cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="497"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="751"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Myeloproliferative disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="497"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="751"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Neuroendocrine carcinoma of the skin</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="497"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="751"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Ovarian adenoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="497"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="751"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="497"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="751"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1248"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="497"/>
                <counts group_id="E3" events="5" subjects_affected="4" subjects_at_risk="507"/>
                <counts group_id="E4" events="5" subjects_affected="4" subjects_at_risk="751"/>
                <counts group_id="E5" events="7" subjects_affected="6" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="497"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="507"/>
                <counts group_id="E4" events="6" subjects_affected="6" subjects_at_risk="751"/>
                <counts group_id="E5" events="6" subjects_affected="6" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="497"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="507"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="751"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="497"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="507"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="751"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="497"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="751"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="497"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="751"/>
                <counts group_id="E5" events="4" subjects_affected="3" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="497"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="751"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="497"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="751"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Dysarthria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="497"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="751"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Grand mal convulsion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="497"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="751"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Monoparesis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="497"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="751"/>
                <counts group_id="E5" events="3" subjects_affected="2" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Altered state of consciousness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="497"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="751"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="497"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="751"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="497"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="751"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Cerebrospinal fluid leakage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="497"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="751"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Cerebrovascular disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="497"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="751"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="497"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="751"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Haemorrhage intracranial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="497"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="751"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Hemiparesis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="497"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="751"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="497"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="751"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Lumbar radiculopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="497"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="751"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Lupus encephalitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="497"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="751"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Memory impairment</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="497"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="751"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Motor dysfunction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="497"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="751"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Myasthenia gravis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="497"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="751"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Neuropsychiatric lupus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="497"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="751"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Optic neuritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="497"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="751"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Polyneuropathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="497"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="751"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Radiculitis brachial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="497"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="751"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Radiculopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="497"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="751"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Seizure anoxic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="497"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="751"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Sinus headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="497"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="751"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Thecal sac compression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="497"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="751"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Thoracic outlet syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="497"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="751"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Transverse sinus thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="497"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="751"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>VIIth nerve paralysis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="497"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="751"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1248"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion spontaneous</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="497"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="751"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Foetal death</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="497"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="751"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Premature delivery</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="497"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="751"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1248"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="497"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="507"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="751"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="497"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="507"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="751"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Psychotic disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="497"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="751"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="497"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="751"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1248"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Lupus nephritis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="244"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="497"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="751"/>
                <counts group_id="E5" events="6" subjects_affected="6" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="497"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="507"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="751"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="497"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="507"/>
                <counts group_id="E4" events="3" subjects_affected="2" subjects_at_risk="751"/>
                <counts group_id="E5" events="4" subjects_affected="3" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="497"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="751"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Glomerulonephritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="497"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="751"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Glomerulonephritis membranoproliferative</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="497"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="751"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Kidney fibrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="497"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="751"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Nephritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="497"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="751"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Renal colic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="497"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="751"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Stress urinary incontinence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="497"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="751"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1248"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Ovarian cyst</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="497"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="507"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="751"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Endometriosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="497"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="751"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Cervical dysplasia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="497"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="751"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Menorrhagia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="497"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="751"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Uterine polyp</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="497"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="751"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Adenomyosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="497"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="751"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Endometrial hyperplasia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="497"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="751"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Pelvic pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="497"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="751"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Uterine haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="497"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="751"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Vaginal prolapse</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="497"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="751"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1248"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="497"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="751"/>
                <counts group_id="E5" events="5" subjects_affected="5" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="497"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="751"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="497"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="507"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="751"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Pleurisy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="497"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="751"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Acute pulmonary oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="497"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="751"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="497"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="751"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="497"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="751"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="497"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="751"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Chronic respiratory failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="497"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="751"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Dyspnoea exertional</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="497"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="751"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Emphysema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="497"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="751"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Laryngeal stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="497"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="751"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="497"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="751"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Pulmonary arterial hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="497"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="751"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Pulmonary hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="497"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="751"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="497"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="751"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Wheezing</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="497"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="751"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1248"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin ulcer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="497"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="751"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Cutaneous vasculitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="497"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="751"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Blister</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="497"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="751"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Chronic cutaneous lupus erythematosus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="497"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="751"/>
                <counts group_id="E5" events="2" subjects_affected="1" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Pruritus generalised</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="497"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="751"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Systemic lupus erythematosus rash</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="497"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="751"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="497"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="751"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1248"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Abortion induced</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="497"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="751"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Cholecystectomy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="497"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="751"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Hip arthroplasty</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="497"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="751"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Joint arthroplasty</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="497"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="751"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Polymedication</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="497"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="751"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Shoulder operation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="497"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="751"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1248"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="497"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="507"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="751"/>
                <counts group_id="E5" events="5" subjects_affected="5" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="497"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="751"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Venous thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="497"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="751"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Arterial occlusive disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="497"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="751"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="497"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="751"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="497"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="751"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Temporal arteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="497"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="751"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Venous thrombosis limb</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="497"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="751"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1248"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA17.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="177" subjects_at_risk="244"/>
                <counts group_id="E2" subjects_affected="296" subjects_at_risk="497"/>
                <counts group_id="E3" subjects_affected="306" subjects_at_risk="507"/>
                <counts group_id="E4" subjects_affected="483" subjects_at_risk="751"/>
                <counts group_id="E5" subjects_affected="779" subjects_at_risk="1248"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="80" subjects_affected="39" subjects_at_risk="244"/>
                <counts group_id="E2" events="86" subjects_affected="59" subjects_at_risk="497"/>
                <counts group_id="E3" events="79" subjects_affected="62" subjects_at_risk="507"/>
                <counts group_id="E4" events="159" subjects_affected="101" subjects_at_risk="751"/>
                <counts group_id="E5" events="245" subjects_affected="160" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="41" subjects_affected="27" subjects_at_risk="244"/>
                <counts group_id="E2" events="58" subjects_affected="47" subjects_at_risk="497"/>
                <counts group_id="E3" events="47" subjects_affected="34" subjects_at_risk="507"/>
                <counts group_id="E4" events="88" subjects_affected="61" subjects_at_risk="751"/>
                <counts group_id="E5" events="146" subjects_affected="108" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="45" subjects_affected="22" subjects_at_risk="244"/>
                <counts group_id="E2" events="43" subjects_affected="32" subjects_at_risk="497"/>
                <counts group_id="E3" events="38" subjects_affected="29" subjects_at_risk="507"/>
                <counts group_id="E4" events="83" subjects_affected="51" subjects_at_risk="751"/>
                <counts group_id="E5" events="126" subjects_affected="83" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="24" subjects_affected="17" subjects_at_risk="244"/>
                <counts group_id="E2" events="22" subjects_affected="19" subjects_at_risk="497"/>
                <counts group_id="E3" events="22" subjects_affected="21" subjects_at_risk="507"/>
                <counts group_id="E4" events="46" subjects_affected="38" subjects_at_risk="751"/>
                <counts group_id="E5" events="68" subjects_affected="57" subjects_at_risk="1248"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="140" subjects_affected="66" subjects_at_risk="244"/>
                <counts group_id="E2" events="126" subjects_affected="76" subjects_at_risk="497"/>
                <counts group_id="E3" events="120" subjects_affected="82" subjects_at_risk="507"/>
                <counts group_id="E4" events="260" subjects_affected="148" subjects_at_risk="751"/>
                <counts group_id="E5" events="386" subjects_affected="224" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="124" subjects_affected="56" subjects_at_risk="244"/>
                <counts group_id="E2" events="88" subjects_affected="61" subjects_at_risk="497"/>
                <counts group_id="E3" events="90" subjects_affected="62" subjects_at_risk="507"/>
                <counts group_id="E4" events="214" subjects_affected="118" subjects_at_risk="751"/>
                <counts group_id="E5" events="302" subjects_affected="179" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="56" subjects_affected="38" subjects_at_risk="244"/>
                <counts group_id="E2" events="65" subjects_affected="42" subjects_at_risk="497"/>
                <counts group_id="E3" events="67" subjects_affected="45" subjects_at_risk="507"/>
                <counts group_id="E4" events="123" subjects_affected="83" subjects_at_risk="751"/>
                <counts group_id="E5" events="188" subjects_affected="125" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="38" subjects_affected="34" subjects_at_risk="244"/>
                <counts group_id="E2" events="38" subjects_affected="35" subjects_at_risk="497"/>
                <counts group_id="E3" events="41" subjects_affected="35" subjects_at_risk="507"/>
                <counts group_id="E4" events="79" subjects_affected="69" subjects_at_risk="751"/>
                <counts group_id="E5" events="117" subjects_affected="104" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="40" subjects_affected="25" subjects_at_risk="244"/>
                <counts group_id="E2" events="48" subjects_affected="41" subjects_at_risk="497"/>
                <counts group_id="E3" events="48" subjects_affected="38" subjects_at_risk="507"/>
                <counts group_id="E4" events="88" subjects_affected="63" subjects_at_risk="751"/>
                <counts group_id="E5" events="136" subjects_affected="104" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="16" subjects_affected="15" subjects_at_risk="244"/>
                <counts group_id="E2" events="24" subjects_affected="22" subjects_at_risk="497"/>
                <counts group_id="E3" events="23" subjects_affected="21" subjects_at_risk="507"/>
                <counts group_id="E4" events="39" subjects_affected="36" subjects_at_risk="751"/>
                <counts group_id="E5" events="63" subjects_affected="58" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="244"/>
                <counts group_id="E2" events="21" subjects_affected="19" subjects_at_risk="497"/>
                <counts group_id="E3" events="23" subjects_affected="17" subjects_at_risk="507"/>
                <counts group_id="E4" events="37" subjects_affected="31" subjects_at_risk="751"/>
                <counts group_id="E5" events="58" subjects_affected="50" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" events="16" subjects_affected="14" subjects_at_risk="244"/>
                <counts group_id="E2" events="17" subjects_affected="15" subjects_at_risk="497"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="507"/>
                <counts group_id="E4" events="24" subjects_affected="22" subjects_at_risk="751"/>
                <counts group_id="E5" events="41" subjects_affected="37" subjects_at_risk="1248"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="47" subjects_affected="34" subjects_at_risk="244"/>
                <counts group_id="E2" events="32" subjects_affected="31" subjects_at_risk="497"/>
                <counts group_id="E3" events="32" subjects_affected="32" subjects_at_risk="507"/>
                <counts group_id="E4" events="79" subjects_affected="66" subjects_at_risk="751"/>
                <counts group_id="E5" events="111" subjects_affected="97" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="40" subjects_affected="24" subjects_at_risk="244"/>
                <counts group_id="E2" events="44" subjects_affected="36" subjects_at_risk="497"/>
                <counts group_id="E3" events="38" subjects_affected="30" subjects_at_risk="507"/>
                <counts group_id="E4" events="78" subjects_affected="54" subjects_at_risk="751"/>
                <counts group_id="E5" events="122" subjects_affected="90" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Systemic lupus erythematosus</sub_title>
                <counts group_id="E1" events="19" subjects_affected="15" subjects_at_risk="244"/>
                <counts group_id="E2" events="26" subjects_affected="18" subjects_at_risk="497"/>
                <counts group_id="E3" events="30" subjects_affected="23" subjects_at_risk="507"/>
                <counts group_id="E4" events="49" subjects_affected="38" subjects_at_risk="751"/>
                <counts group_id="E5" events="75" subjects_affected="56" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="21" subjects_affected="15" subjects_at_risk="244"/>
                <counts group_id="E2" events="17" subjects_affected="15" subjects_at_risk="497"/>
                <counts group_id="E3" events="21" subjects_affected="19" subjects_at_risk="507"/>
                <counts group_id="E4" events="42" subjects_affected="34" subjects_at_risk="751"/>
                <counts group_id="E5" events="59" subjects_affected="49" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" events="14" subjects_affected="13" subjects_at_risk="244"/>
                <counts group_id="E2" events="20" subjects_affected="18" subjects_at_risk="497"/>
                <counts group_id="E3" events="7" subjects_affected="6" subjects_at_risk="507"/>
                <counts group_id="E4" events="21" subjects_affected="19" subjects_at_risk="751"/>
                <counts group_id="E5" events="41" subjects_affected="37" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Bursitis</sub_title>
                <counts group_id="E1" events="24" subjects_affected="15" subjects_at_risk="244"/>
                <counts group_id="E2" events="11" subjects_affected="9" subjects_at_risk="497"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="507"/>
                <counts group_id="E4" events="31" subjects_affected="22" subjects_at_risk="751"/>
                <counts group_id="E5" events="42" subjects_affected="31" subjects_at_risk="1248"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="66" subjects_affected="46" subjects_at_risk="244"/>
                <counts group_id="E2" events="84" subjects_affected="67" subjects_at_risk="497"/>
                <counts group_id="E3" events="80" subjects_affected="57" subjects_at_risk="507"/>
                <counts group_id="E4" events="146" subjects_affected="103" subjects_at_risk="751"/>
                <counts group_id="E5" events="230" subjects_affected="170" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="26" subjects_affected="20" subjects_at_risk="244"/>
                <counts group_id="E2" events="30" subjects_affected="23" subjects_at_risk="497"/>
                <counts group_id="E3" events="25" subjects_affected="23" subjects_at_risk="507"/>
                <counts group_id="E4" events="51" subjects_affected="43" subjects_at_risk="751"/>
                <counts group_id="E5" events="81" subjects_affected="66" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" events="15" subjects_affected="13" subjects_at_risk="244"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="497"/>
                <counts group_id="E3" events="13" subjects_affected="12" subjects_at_risk="507"/>
                <counts group_id="E4" events="28" subjects_affected="25" subjects_at_risk="751"/>
                <counts group_id="E5" events="37" subjects_affected="34" subjects_at_risk="1248"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="17" subjects_affected="16" subjects_at_risk="244"/>
                <counts group_id="E2" events="23" subjects_affected="23" subjects_at_risk="497"/>
                <counts group_id="E3" events="16" subjects_affected="15" subjects_at_risk="507"/>
                <counts group_id="E4" events="33" subjects_affected="31" subjects_at_risk="751"/>
                <counts group_id="E5" events="56" subjects_affected="54" subjects_at_risk="1248"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="25" subjects_affected="21" subjects_at_risk="244"/>
                <counts group_id="E2" events="31" subjects_affected="30" subjects_at_risk="497"/>
                <counts group_id="E3" events="43" subjects_affected="32" subjects_at_risk="507"/>
                <counts group_id="E4" events="68" subjects_affected="53" subjects_at_risk="751"/>
                <counts group_id="E5" events="99" subjects_affected="83" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="24" subjects_affected="15" subjects_at_risk="244"/>
                <counts group_id="E2" events="11" subjects_affected="9" subjects_at_risk="497"/>
                <counts group_id="E3" events="16" subjects_affected="14" subjects_at_risk="507"/>
                <counts group_id="E4" events="40" subjects_affected="29" subjects_at_risk="751"/>
                <counts group_id="E5" events="51" subjects_affected="38" subjects_at_risk="1248"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" events="20" subjects_affected="13" subjects_at_risk="244"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="497"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="507"/>
                <counts group_id="E4" events="24" subjects_affected="17" subjects_at_risk="751"/>
                <counts group_id="E5" events="31" subjects_affected="24" subjects_at_risk="1248"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="19" subjects_affected="17" subjects_at_risk="244"/>
                <counts group_id="E2" events="28" subjects_affected="26" subjects_at_risk="497"/>
                <counts group_id="E3" events="27" subjects_affected="26" subjects_at_risk="507"/>
                <counts group_id="E4" events="46" subjects_affected="43" subjects_at_risk="751"/>
                <counts group_id="E5" events="74" subjects_affected="69" subjects_at_risk="1248"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>UCB</name_or_title>
      <organization>Cares</organization>
      <phone>+1844 599 ext 2273</phone>
      <email>UCBCares@ucb.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

